Literature DB >> 24521605

Reply to Tan et al.

David T Kuhar1, Kimberly A Struble, David K Henderson.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24521605      PMCID： PMC4601095          DOI： 10.1086/675350

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


× No keyword cloud information.
  5 in total

1.  Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.

Authors:  William Tosini; Philippe Muller; Thierry Prazuck; Ghania Benabdelmoumen; Eric Peyrouse; Bernard Christian; Yann Quertainmont; Elisabeth Bouvet; Christian Rabaud
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

2.  Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.

Authors:  Kenneth H Mayer; Matthew J Mimiaga; Marcy Gelman; Chris Grasso
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

3.  Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting.

Authors:  Darrell H S Tan; Blessing Goddey-Erikefe; Deborah Yoong; Mark Naccarato; Susan McIntyre; Roohi Qureshi; Kevin Gough
Journal:  Infect Control Hosp Epidemiol       Date:  2014-03       Impact factor: 3.254

4.  Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.

Authors:  J McAllister; P Read; A McNulty; W W Y Tong; A Ingersoll; A Carr
Journal:  HIV Med       Date:  2013-09-06       Impact factor: 3.180

5.  Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.

Authors:  David T Kuhar; David K Henderson; Kimberly A Struble; Walid Heneine; Vasavi Thomas; Laura W Cheever; Ahmed Gomaa; Adelisa L Panlilio
Journal:  Infect Control Hosp Epidemiol       Date:  2013-09       Impact factor: 3.254
  5 in total
  1 in total

Review 1.  Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).

Authors:  Susan E Beekmann; David K Henderson
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.